ArticleFrontiers in nutrition2026
Acupoint catgut embedding exerts node-dependent effects on leptin resistance-related signaling and the ghrelin-GOAT pathway in obese mice.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity is a major metabolic health problem with limited effective treatments. Acupoint catgut embedding (ACE) has shown therapeutic potential; however, its underlying mechanisms remain unclear. This study aimed to investigate the effects of ACE on leptin resistance and the Ghrelin-GOAT pathway in obese mice. Methods: Diet-induced obesity was established in C57BL/6 J mice. A total of 51 mice were included in the final analysis across six groups: normal control, obese model control, ST36 sham ACE, ST36 verum ACE, ST25 ACE, and ST25 + ST36 ACE. ACE was administered once weekly for 5 weeks. Body weight, Lee's index, and daily food intake were recorded. Serum and cerebrospinal fluid (CSF) leptin levels were measured to assess peripheral and central leptin availability. Hypothalamic SOCS3 and PTP1B protein expression and POMC/NPY mRNA levels were evaluated. Ghrelin-related indicators in gastric tissue and hypothalamus were also assessed. Results: At week 1, body weight and Lee's index were lower in the ST36 verum ACE group than in the ST25 + ST36 group ( Conclusion: ACE may increase central leptin availability, downregulate SOCS3 and PTP1B, regulate hypothalamic POMC/NPY expression, and modulate the ghrelin-GOAT pathway, supporting a node-dependent, multi-target mechanism underlying its anti-obesity effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.